Literature DB >> 30989254

Underpowered or negative? A crucial distinction. Reply to Dollerup OL, Treebak JT, Jessen N [letter].

Niels J Connell1, Riekelt H Houtkooper2, Patrick Schrauwen3.   

Abstract

Keywords:  Clinical trial; Human; NAD+ metabolism

Mesh：

Substances：

Year:  2019        PMID： 30989254     DOI： 10.1007/s00125-019-4868-3

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  3 in total

1.  Underpowered or negative? A crucial distinction.

Authors:  Ole L Dollerup; Jonas T Treebak; Niels Jessen
Journal:  Diabetologia       Date:  2019-03-25       Impact factor: 10.122

2.  A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.

Authors:  Ole L Dollerup; Britt Christensen; Mads Svart; Mark S Schmidt; Karolina Sulek; Steffen Ringgaard; Hans Stødkilde-Jørgensen; Niels Møller; Charles Brenner; Jonas T Treebak; Niels Jessen
Journal:  Am J Clin Nutr       Date:  2018-08-01       Impact factor: 7.045

Review 3.  NAD+ metabolism as a target for metabolic health: have we found the silver bullet?

Authors:  Niels J Connell; Riekelt H Houtkooper; Patrick Schrauwen
Journal:  Diabetologia       Date:  2019-02-16       Impact factor: 10.122
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.